GlaxoSmithKline plc announced that Luke Miels has been appointed President, Global Pharmaceuticals, GSK. He will be responsible for a portfolio of medicines and vaccines with annual sales of more than £15 billion and operations in over 100 markets. Luke will report to Emma Walmsley, who is currently CEO Designate and will become CEO of GSK in April 2017. Luke is currently Executive Vice President (EVP) of AstraZeneca's European business and was previously EVP, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.